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Background
We constructed recombinants of the Japanese-licensed
Tokyo 172 strain of BCG and the replication-competent
vaccinia virus strain LC16m8Δ (m8Δ) (a genetically stable
variant of Japanese licensed smallpox vaccine LC16m8) to
express SIV genes. We then evaluated the protective effi-
cacy of these recombinants against challenge with patho-
genic, neutralization resistant SIVmac251.
Methods
Indian rhesus macaques were immunized with rBCG-SIV
expressing SIV Gag, Env, or Rev-Tat-Nef (RTN) fusion
proteins via subcutaneous injection, followed with two
boosts with the Gag-, Env-, RT-, or RTN-expressing m8Δ
by skin scarification. Eight weeks after the 2nd boost,
macaques were challenged up to 5 times with a low dose
of SIVmac251 by the rectal route. Cellular and humoral
immune responses were analyzed by standard methods.
Plasma SIV RNA and cell-associated SIV proviral DNA in
peripheral blood and various tissues were monitored by
quantitative PCR.
Results
Env binding antibodies were elicited at similar levels in all
vaccinated macaques after m8Δ boost, but neutralizing Ab
against SIVmac239 was not detected. Robust SIV-specific
CD4+ and CD8+ effecter memory T cell responses were
elicited and maintained at high level until SIV challenge.
One vaccinated animal had potent CD8+ T cells that sup-
pressed SIVmac239 replication in vitro. Plasma viraemia
was not detected in this animal, even after CD8+ T cell
depletion throughout the follow-up period. Protection was
confirmed by lack of detectable cell-associated provirus in
various organs. A second vaccinated monkey became
i n f e c t e d ,b u tv i r a ll o a dr e m a i n e df r o mo n et ot w ol o g s
lower than control monkeys.
Conclusion
Vaccine-induced SIV specific T cell responses appear to be
effective against SIV challenge. Importantly, our results
suggest that a vaccine regimen based on an rBCG prime
and vaccinia m8Δ boost (both liscensed vaccine platforms
with a long track record of safety in humans) should be
explored as a safe and valuable means for efficacious HIV/
AIDS vaccine.
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